School of Sport Economics and Management, Central University of Finance and Economics, 39 South College Road, Haidian District, Beijing, 100081, People's Republic of China.
Youth Sports Research Center, China Institute of Sport Science, Beijing, People's Republic of China.
Eur J Nutr. 2019 Dec;58(8):3079-3090. doi: 10.1007/s00394-018-1853-4. Epub 2018 Oct 31.
Some studies have investigated the association between soy and isoflavones consumption and breast cancer survival, but the results are far from conclusive. Accordingly, we performed a systematic review and meta-analysis to explore this issue.
We performed a comprehensive search of Web of Science, PubMed, and Embase from inception to January 2018. The summary hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using a random effects model.
A total of 12 articles were included, which reported overall survival (OS), breast cancer specific survival (BCSS), and recurrence in 5770, 2386, and 1500 cases, respectively, among 37,275 women with breast cancer. The summary HR (95% CI) for the association (highest vs. lowest) of pre-diagnosis soy and isoflavones consumption with OS and BCSS was 0.84 (0.71-0.98) and 0.89 (0.74-1.07), respectively. Stratified analyses suggested that the reduced OS was more easily detected in studies that focused on post-menopausal patients. No significant association was found between post-diagnosis soy and isoflavones consumption with OS and BCSS, with summary HRs (95% CIs) of 0.80 (0.62-1.04) and 0.83 (0.64-1.07), respectively. Pre- and post-diagnosis soy isoflavones consumption were associated with reduced risk of recurrence.
This study provides limited evidence that pre-diagnosis soy and isoflavones intake is associated with a small reduction in post-menopausal breast cancer OS.
一些研究调查了大豆和异黄酮的摄入与乳腺癌生存之间的关系,但结果远未得出结论。因此,我们进行了一项系统评价和荟萃分析来探讨这个问题。
我们全面检索了 Web of Science、PubMed 和 Embase 从成立到 2018 年 1 月的文献。使用随机效应模型估计汇总风险比(HR)和 95%置信区间(CI)。
共纳入 12 项研究,分别报道了 5770 例、2386 例和 1500 例患者的总生存(OS)、乳腺癌特异性生存(BCSS)和复发情况,这些患者均为 37275 例乳腺癌女性。诊断前大豆和异黄酮摄入与 OS 和 BCSS 关联的汇总 HR(95%CI)分别为 0.84(0.71-0.98)和 0.89(0.74-1.07)。分层分析表明,在关注绝经后患者的研究中,OS 降低更容易被发现。诊断后大豆和异黄酮摄入与 OS 和 BCSS 无显著关联,汇总 HR(95%CI)分别为 0.80(0.62-1.04)和 0.83(0.64-1.07)。诊断前和诊断后大豆异黄酮的摄入与复发风险降低相关。
本研究提供的有限证据表明,诊断前大豆和异黄酮的摄入与绝经后乳腺癌 OS 略有降低有关。